Pearl Medical Practice PLLC

Pearl Medical Practice PLLC was paid $4.29M by Medicaid between Jan 2018 and Dec 2024, across 72 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 34% of everything it billed.

Compared with peers

Next to other Physician Assistant providers in Kentucky

Rank by total paid#12 of 214

Median peer was paid$134K

This provider vs. median32×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	28,751	$659K
2019	44,018	$709K
2020	45,398	$882K
2021	45,275	$807K
2022	31,586	$483K
2023	23,963	$386K
2024incomplete	18,802	$363K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	34%	14,627	11,546	$1.47M
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	22%	26,827	22,877	$950K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	22%	23,820	19,440	$940K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	6.6%	12,060	10,273	$283K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	4.0%	1,957	1,730	$171K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	3.7%	4,129	2,432	$158K
99396	Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years	2.3%	1,621	1,514	$97K
99429		<1%	434	421	$29K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	<1%	388	346	$27K
99441		<1%	878	792	$19K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	1,405	946	$14K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	1,369	763	$14K

60 more codes

U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	1,425	$14K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	1,001	$11K
99215	Doctor's office visit, returning patient (complex)	<1%	178	$10K
99497		<1%	239	$7K
99395	Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years	<1%	108	$7K
82962		<1%	4,237	$7K
90674		<1%	406	$6K
99406		<1%	1,015	$6K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	285	$4K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	165	$4K
90756		<1%	308	$3K
84443	Thyroid stimulating hormone (TSH)	<1%	345	$3K
84481		<1%	338	$3K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	45	$3K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	361	$3K
90686		<1%	264	$3K
99203	Doctor's office visit, new patient (routine)	<1%	41	$3K
82607		<1%	255	$2K
82746		<1%	252	$2K
84439		<1%	338	$2K
99442		<1%	45	$2K
82728		<1%	189	$1K
82948		<1%	535	$848.77
86769		<1%	19	$629.40
84403		<1%	40	$607.27
90658		<1%	35	$514.26
84153		<1%	41	$424.61
90688		<1%	25	$421.90
82043		<1%	109	$350.65
96160		<1%	94	$177.66
36415	Collection of venous blood by venipuncture	<1%	332	$173.34
86803		<1%	27	$134.17
86705		<1%	27	$110.67
86709		<1%	27	$105.86
1159F		<1%	31,154	$32.47
G8752	Most recent systolic blood pressure < 140 mmhg	<1%	16,469	$15.60
G0008	Administration of influenza virus vaccine	<1%	58	$13.66
G8427	Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications	<1%	3,614	$10.51
84436		<1%	113	$6.87
84479		<1%	111	$6.47
1160F		<1%	34,605	$3.28
3077F		<1%	2,590	$0.01
3078F		<1%	3,202	$0.01
3080F		<1%	2,712	$0.01
1125F		<1%	6,485	$0.01
3074F		<1%	3,677	$0.01
G8753	Most recent systolic blood pressure >= 140 mmhg	0%	4,485	$0.00
G8431	Screening for depression is documented as being positive and a follow-up plan is documented	0%	206	$0.00
3085F		0%	13	$0.00
3288F		0%	17	$0.00
G8754	Most recent diastolic blood pressure < 90 mmhg	0%	17,936	$0.00
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	0%	54	$0.00
G8755	Most recent diastolic blood pressure >= 90 mmhg	0%	2,860	$0.00
G8510	Screening for depression is documented as negative, a follow-up plan is not required	0%	1,241	$0.00
3079F		0%	1,943	$0.00
3075F		0%	1,516	$0.00
1101F		0%	18	$0.00
1170F		0%	20	$0.00
1034F		0%	14	$0.00
1111F		0%	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialOMORUYI, OSAWARU (PRESIDENT)

Same official

Other billing entities under OMORUYI, OSAWARU

Full network →

Provider	Location	Paid
Pearl Geriatrics and Palliative Medicine, PSC	Louisville, KY	$809K
Medical Products Group, LLC	Wheaton, IL	$245K
Pearl Diagnostic Laboratory, LLC	Louisville, KY	$21K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.